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There is a substantial need for molecularly defined tumor
antigens to prime cytotoxic T cells in vivo for cancer immu-
notherapy, especially in the case of tumor entities for
which only few tumor antigens have been defined so far.
Here, we present the "Tübingen approach" to identify,
select and validate large numbers of HLA class I-associated
peptides derived from tumor-associated antigens. Step 1 is
the identification of naturally presented HLA-associated
peptides directly from primary tumor cells. Step 2 is selec-
tion of tumor-associated peptides from step 1 by differen-
tial gene expression analysis and data mining. Step 3 is
validation of selected candidates by monitoring in vivo T-
cell responses. Our approach combines methods from
genomics, proteomics, bioinformatics and T-cell immu-
nology. The aim is to develop effective immunotherapeu-
tics consisting of multiple tumor-associated epitopes in
order to induce a broad and specific immune response
against cancer cells.
Immatics biotechnologies, a privately owned spin-off
from the University of Tübingen, is dedicated to the devel-
opment of immunotherapeutics based on several
approaches, of which one is presented here. In February
2004, the company received substantial private funding in
its first financing round to start operations. http://
www.immatics.com
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